-
Drug Discovery & Therapeutics2 weeks agoTurning Process Understanding Into Control of Lipid Nanoparticles
Splitting lipid nanoparticle manufacturing into multiple mixing steps can help better control the size, shape, and stability of particles, with the aim of improving product quality...
-
Drug Discovery & Therapeutics2 weeks agoA new startup takes aim at a suspected culprit in autoimmune disease
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune conditions: diseased T cells.
-
Drug Discovery & Therapeutics2 weeks agoPfizer partners with Enodia Therapeutics in $500m drug deal
Under the partnership, Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets. Pfizer will take full responsibility...
-
Drug Discovery & Therapeutics2 weeks agoPreclinical Pulse: The research catching our eye in October 2026
Find out about six preclinical assets that caught our attention in the October edition of Labiotech's Preclinical Pulse. The post Preclinical Pulse: The research catching our...
-
Drug Discovery & Therapeutics2 weeks agoEnodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small Molecules
Backed by multiple Sec61 inhibitor families, proteomics and cryo-EM datasets, and machine learning-driven design, Enodia Therapeutics’ platform is the foundation of a new research collaboration and...
-
Drug Discovery & Therapeutics2 weeks agoRoche extends China deal streak with $1B pact for RNAi obesity drug
An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower...
-
Drug Discovery & Therapeutics2 weeks agoRoche expands obesity R&D footprint with Rona deal worth $1B+
Roche has gained access to a genetic obesity approach from China's Rona Therapeutics for up to $100 million in upfront and near-term payments.
-
Drug Discovery & Therapeutics2 weeks agoRoche adds another obesity drug with $1.16bn Rona deal
Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ALK7.
-
Drug Discovery & Therapeutics2 weeks agoIn vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles
Nature Biotechnology, Published online: 13 October 2026; doi:10.1038/s41587-026-03310-1Chimeric antigen receptor natural killer cells to treat autoimmune disease and cancer are generated in vivo.
-
Drug Discovery & Therapeutics2 weeks agoFilling the massive AI drug discovery data gap
Nature Reviews Drug Discovery, Published online: 12 October 2026; doi:10.1038/d41573-026-00137-yCharlotte Deane, co-leader of the OpenBind initiative, discusses the need for more protein–small molecule binding data.
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
